Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/5/2025

Reversing Non-Alcoholic Steatohepatitis (NASH)

Introduction to NASH Reversal

  • Lifestyle modification through diet and exercise to achieve sustained weight loss of ≥10% total body weight is the only intervention with Level 1 evidence for reversing NASH, with proven ability to resolve steatohepatitis and regress fibrosis, as recommended by the American Gastroenterological Association 1

Weight Loss Targets for Histologic Reversal

  • A weight loss of ≥5% total body weight (TBW) decreases hepatic steatosis in 65% of patients, as reported by the American Gastroenterological Association 1
  • A weight loss of ≥7% TBW achieves NASH resolution in 64% of patients, according to the American Gastroenterological Association 1
  • A weight loss of ≥10% TBW results in fibrosis regression (at least 1 stage) in 45% of patients, with the remaining 55% showing fibrosis stabilization, as stated by the American Gastroenterological Association 1

Dietary Interventions

  • Implement a hypocaloric diet targeting 1200-1500 kcal/day for women and 1400-1500 kcal/day for men, or reduce baseline intake by 500-1000 kcal/day, as recommended by the American Gastroenterological Association 1
  • Adopt a Mediterranean dietary pattern including daily consumption of vegetables, fruits, unsweetened high-fiber cereals, nuts, fish or white meat, and olive oil, as suggested by the American Heart Association 2
  • Completely eliminate sugar-sweetened beverages and limit ultra-processed foods rich in sugars and saturated fat, as advised by the American Heart Association 2

Exercise Prescription

  • Prescribe at least 150 minutes per week of moderate-intensity exercise or 75 minutes per week of vigorous-intensity activity, as recommended by the American College of Sports Medicine 1, 2

Pharmacologic Interventions for NASH Reversal

  • For patients with biopsy-proven NASH and significant fibrosis (≥F2), pioglitazone 30-45 mg daily for 18-24 months is the evidence-based first-line pharmacotherapy, as stated by the American Association for the Study of Liver Diseases 4, 5
  • Semaglutide 0.4 mg daily achieved NASH resolution without worsening fibrosis in 59% of patients versus 17% with placebo, as reported by the American Gastroenterological Association 5
  • Vitamin E 800 IU daily improved steatohepatitis in patients with biopsy-proven NASH without type 2 diabetes, as suggested by the American Gastroenterological Association 5

Structured Weight Loss Programs

  • Intensive lifestyle intervention programs are significantly more effective than general education alone, as reported by the Mayo Clinic 3
  • Structured weight loss programs and anti-obesity medications are usually more successful for weight loss than office-based efforts during regular visits, as stated by the American Gastroenterological Association 5

Bariatric Surgery

  • Bariatric surgery should be considered for appropriate individuals with clinically significant fibrosis and obesity with comorbidities, as recommended by the American Gastroenterological Association 5, 2

Multidisciplinary Management Approach

  • Optimal care requires a multidisciplinary team integrating primary care, hepatology, obesity medicine, and endocrinology/diabetology via well-defined care pathways, as suggested by the American Gastroenterological Association 6, 2
  • Aggressively screen and manage diabetes, dyslipidemia, and hypertension, as advised by the American Heart Association 2

Risk Stratification and Monitoring

  • Stratify patients using FIB-4 score, liver stiffness measurement (LSM), or liver biopsy, as recommended by the American Association for the Study of Liver Diseases 2, 5
  • Patients with advanced fibrosis (F3) require hepatocellular carcinoma surveillance with imaging every 6 months, as suggested by the American Association for the Study of Liver Diseases 2